Home › Funds › Krensavage Asset Management, LLC › REGN
Krensavage Asset Management, LLC position in REGN
REGENERON PHARMACEUTICALS · Health Care
Krensavage Asset Management, LLC reported holding 6,000 shares of REGN (REGENERON PHARMACEUTICALS) in its Q2 2026 13F filing — a position valued at US$3.7M, representing 1.42% of its reported portfolio and ranking #14 among its reported holdings. Krensavage Asset Management, LLC has disclosed REGN holdings in 10 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Krensavage Asset Management, LLC's REGN position evolved
Krensavage Asset Management, LLC first disclosed a stake in REGN in Q3 2023 at 47,256 shares (US$38.9M). The position peaked in Q4 2023 at 47,256 shares, worth US$41.5M. Across 10 filings, Krensavage Asset Management, LLC increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 6,000 shares valued at US$3.7M — an increase of 2,000 shares quarter over quarter.. Notable position changes include a 74% trim in Q1 2024 (shares rose 9% over the following quarter), a 96% trim in Q3 2024 (shares fell 32% over the following quarter), a 50% increase in Q2 2026 (shares rose 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 47.26K | $38.89M | New |
| Q4 2023 | 47.26K | $41.50M | Hold |
| Q1 2024 | 12.49K | $12.03M | Reduce |
| Q2 2024 | 7.85K | $8.25M | Reduce |
| Q3 2024 | 353 | $371.00K | Reduce |
| Q2 2025 | 4.00K | $2.10M | New |
| Q3 2025 | 4.00K | $2.25M | Hold |
| Q4 2025 | 4.00K | $3.09M | Hold |
| Q1 2026 | 4.00K | $3.09M | Hold |
| Q2 2026 | 6.00K | $3.74M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About REGN and 13F data
REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 31 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), LOOMIS SAYLES & CO L P (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding REGN
- Dodge & Cox 4.87M sh · $3.04B · Q2 2026
- DODGE & COX 4.87M sh · $3.04B · Q2 2026
- LOOMIS SAYLES & CO L P 1.86M sh · $1.16B · Q2 2026
More on Krensavage Asset Management, LLC
FAQ
How long has Krensavage Asset Management, LLC held REGN?
Krensavage Asset Management, LLC has disclosed REGN holdings in 10 of the last 12 reported quarters, going back to Q3 2023.
What is Krensavage Asset Management, LLC's current position in REGN?
As of Q2 2026, Krensavage Asset Management, LLC holds 6.00K shares of REGN (REGENERON PHARMACEUTICALS), valued at $3.74M, representing 1.42% of its reported portfolio and ranking #14.
Has Krensavage Asset Management, LLC been buying or selling REGN?
In the latest 13F filing (Q2 2026), Krensavage Asset Management, LLC increased its position in REGN. The position peaked in Q4 2023 at 47.26K shares.
Which other funds hold REGN?
Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, LOOMIS SAYLES & CO L P, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.